Rezaie Alireza R, Giri Hemant
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
J Thromb Haemost. 2020 Dec;18(12):3142-3153. doi: 10.1111/jth.15052. Epub 2020 Sep 9.
Antithrombin (AT) is a major plasma glycoprotein of the serpin superfamily that regulates the proteolytic activity of the procoagulant proteases of both intrinsic and extrinsic pathways. Two important structural features that participate in the regulatory function of AT include a mobile reactive center loop that binds to active site of coagulation proteases, trapping them in the form of inactive covalent complexes, and a basic D-helix that binds to therapeutic heparins and heparan sulfate proteoglycans (HSPGs) on vascular endothelial cells. The binding of D-helix of AT by therapeutic heparins promotes the reactivity of the serpin with coagulation proteases by several orders of magnitude by both a conformational activation of the serpin and a template (bridging) mechanism. In addition to its essential anticoagulant function, AT elicits a potent anti-inflammatory signaling response when it binds to distinct vascular endothelial cell HSPGs, thereby inducing prostacyclin synthesis. Syndecans-4 has been found as a specific membrane-bound HSPG receptor on endothelial cells that relays the signaling effect of AT to the relevant second messenger molecules in the signal transduction pathways inside the cell. However, following cleavage by coagulation proteases and/or by spontaneous conversion to a latent form, AT loses both its anti-inflammatory activity and high-affinity interaction with heparin and HSPGs. Interestingly, these low-affinity heparin conformers of AT elicit potent proapoptotic and antiangiogenic activities by also binding to specific HSPGs by unknown mechanisms. This review article will summarize current knowledge about mechanisms through which different conformers of AT exert their serine protease inhibitory and intracellular signaling functions in these biological pathways.
抗凝血酶(AT)是丝氨酸蛋白酶抑制剂超家族的一种主要血浆糖蛋白,可调节内源性和外源性途径的促凝血蛋白酶的蛋白水解活性。参与AT调节功能的两个重要结构特征包括:一个可移动的反应中心环,它与凝血蛋白酶的活性位点结合,以无活性共价复合物的形式捕获它们;以及一个碱性D螺旋,它与血管内皮细胞上的治疗性肝素和硫酸乙酰肝素蛋白聚糖(HSPG)结合。治疗性肝素与AT的D螺旋结合,通过丝氨酸蛋白酶抑制剂的构象激活和模板(桥接)机制,使丝氨酸蛋白酶抑制剂与凝血蛋白酶的反应性提高几个数量级。除了其基本的抗凝功能外,AT与不同的血管内皮细胞HSPG结合时会引发强烈的抗炎信号反应,从而诱导前列环素的合成。Syndecans-4已被发现是内皮细胞上一种特定的膜结合HSPG受体,它将AT的信号作用传递给细胞内信号转导途径中的相关第二信使分子。然而,在被凝血蛋白酶切割和/或自发转化为潜伏形式后,AT失去了其抗炎活性以及与肝素和HSPG的高亲和力相互作用。有趣的是,这些低亲和力的AT肝素构象异构体还通过未知机制与特定的HSPG结合,从而引发强烈的促凋亡和抗血管生成活性。这篇综述文章将总结关于AT的不同构象异构体在这些生物学途径中发挥其丝氨酸蛋白酶抑制和细胞内信号功能的机制的当前知识。